2022 ESMO Congress Research Highlights

In the following videos, faculty from Dana-Farber Cancer Institute review research highlights from the ESMO Congress 2022 held in Paris, France, September 9-13, 2022.


Prostate Cancer Highlights from ESMO 2022

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the genitourinary cancer clinical updates you need to know from ESMO 2022
Jacob Berchuck, MD

Jacob Berchuck, MD

Medical Oncology
Christopher Sweeney, MBBS

Christopher Sweeney, MBBS

Medical Oncology

Bladder Cancer Highlights from ESMO 2022

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the genitourinary cancer clinical updates you need to know from ESMO 2022
Charlene Mantia, MD

Charlene Mantia, MD

Medical Oncology
Joaqium Bellmunt, MD, PhD

Joaqium Bellmunt, MD, PhD

Medical Oncology

Kidney Cancer Highlights from ESMO 2022

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the genitourinary cancer clinical updates you need to know from ESMO 2022
Wenxin Xu, MD

Wenxin Xu, MD

Medical Oncology
Toni Choueiri, MD

Toni Choueiri, MD

Medical Oncology

Testicular Cancer Highlights from ESMO 2022

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the genitourinary cancer clinical updates you need to know from ESMO 2022
Alok Tewari, MD, PhD

Alok Tewari, MD, PhD

Medical Oncology

Toni Choueiri, MD Shares the Latest Data From COSMIC-313

Kidney Cancer triplet slows progression in advanced disease when compared to immunotherapy combo (nivolumab + ipilimumab).
Toni Choueiri, MD

Toni Choueiri, MD

Medical Oncology

Glenn Hanna, MD Shares Phase 2 Study of Nivolumab for High-Risk Oral Leukoplakia

37% of patients with high-risk oral leukoplakia treated with preventative immunotherapy had proliferative leukoplakia regression and demonstrated favorable overall cancer-free survival.
Glenn Hanna, MD

Glenn Hanna, MD

Medical Oncology

Sara Tolany, MD Shares the Latest Breast Cancer Research

Results of monarcHER found abemaciclib + trastuzumab +/- fulvestrant was associated w/numerically improved overall survival when compared to chemo + trastuzumab among pts w/HR+, HER2+ advanced breast cancer.
Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH

Medical Oncology

Sara Tolaney, MD Shares New Study Results in Breast Cancer

Significant improvement in overall survival (OS) results seen in phase 3 TROPiCS study. Sacituzumab Govitecan improved OS from 11.2 months to 14.4 months compared to treatment of choice chemo.
Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH

Medical Oncology

Catherine Marinac, PhD Shares Findings From a Prospective Study of a Multi-Cancer Blood Detection Test

The PATHFINDER study examined if a simple blood test could detect a cancer signal in people ages 50 years and older who were not known to have cancer.
Catherine Marinac, PhD

Catherine Marinac, PhD

Population Sciences

Ben Schlechter, MD Presents Details on the Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Solid Tumors

A phase I/II Trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in response or refractory solid tumors.
Benjamin L. Schlechter, MD

Benjamin L. Schlechter, MD

Medical Oncology